CDK4/6 inhibitors in advanced breast cancer, what is beyond?

被引：4
|
作者：
Mohammed, Amrallah A. [1 ,2 ]
Rashied, Hanaa [3 ]
Elsayed, Fifi Mostafa [4 ]
机构：
[1] Zagazig Univ, Fac Med, Med Oncol Dept, 29 Saad Zaghloul, Zagazig 44519, Egypt
[2] King Salman Armed Forces Hosp, Tabuk City, Saudi Arabia
[3] El Mabra Hosp, Zagazig, Egypt
[4] Suez Canal Univ, Dept Fac Med, Clin Oncol & Nucl Med, Ismailia, Egypt
来源：
ONCOLOGY REVIEWS | 2019年 / 13卷 / 02期
关键词：
Breast cancer; CDK4/6; inhibitors; predictors of response and resistance; RIBOCICLIB PLUS LETROZOLE; KINASE; 4/6; INHIBITOR; 1ST-LINE TREATMENT; ENDOCRINE THERAPY; PALBOCICLIB; ABEMACICLIB; COMBINATION; RESISTANCE; FULVESTRANT; SUPPRESSION;
D O I：
10.4081/oncol.2019.416
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Resistant to hormonal treatment considered the main clinical challenge in the management of advanced breast cancer (ABC). The use of CDK4/6 inhibitors (CDK4/61) may change the treatment landscape. In this mandated review, we will focus on the applicable role of CDK4/6I in the management of HR+/HER2-ABC, mechanisms of resistance, and promising future implementation.
引用
收藏
页码：125 / 133
页数：9
相关论文
共 50 条
  • [31] Cardiac complications of CDK4/6 inhibitors for breast cancer.
    Master, Samip R.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [32] An Update on the Clinical Use of CDK4/6 Inhibitors in Breast Cancer
    Robert, Marie
    Frenel, Jean-Sebastien
    Bourbouloux, Emmanuelle
    Rigaud, Dominique Berton
    Patsouris, Anne
    Augereau, Paule
    Gourmelon, Carole
    Campone, Mario
    DRUGS, 2018, 78 (13) : 1353 - 1362
  • [33] Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer
    George, Mridula A.
    Qureshi, Sadaf
    Omene, Coral
    Toppmeyer, Deborah L.
    Ganesan, Shridar
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [34] CDK4/6 Inhibitors: What Is the Best Cocktail?
    Malumbres, Marcos
    CLINICAL CANCER RESEARCH, 2019, 25 (01) : 6 - 8
  • [35] Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer
    Hehui Fang
    Doudou Huang
    Fang Yang
    Xiaoxiang Guan
    Breast Cancer Research and Treatment, 2018, 168 : 287 - 297
  • [36] Comparative overall survival of CDK4/6 inhibitors in combination with endocrine therapy in advanced breast cancer
    Kappel, Coralea
    Elliott, Mitchell J.
    Kumar, Vikaash
    Nadler, Michelle B.
    Desnoyers, Alexandra
    Amir, Eitan
    SCIENTIFIC REPORTS, 2024, 14 (01)
  • [37] Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer
    Fang, Hehui
    Huang, Doudou
    Yang, Fang
    Guan, Xiaoxiang
    BREAST CANCER RESEARCH AND TREATMENT, 2018, 168 (02) : CP8 - 297
  • [38] Advanced breast cancer treatment after CDK4/6-inhibitors - the experience of a Hospital Center
    Costa, M.
    Valente, A. C.
    Freitas, M.
    Almeida, C.
    Tavares, N.
    Almeida, D.
    Caeiro, C.
    Augusto, I.
    Sousa, I.
    Barbosa, M.
    EUROPEAN JOURNAL OF CANCER, 2022, 175 : S70 - S71
  • [39] Comparative overall survival of CDK4/6 inhibitors in combination with endocrine therapy in advanced breast cancer
    Coralea Kappel
    Mitchell J. Elliott
    Vikaash Kumar
    Michelle B. Nadler
    Alexandra Desnoyers
    Eitan Amir
    Scientific Reports, 14
  • [40] CDK4/6 inhibitors as neoadjuvant treatment in breast cancer-what can we learn?
    Brandao, M.
    Ignatiadis, M.
    ANNALS OF ONCOLOGY, 2018, 29 (12) : 2274 - 2278
12345